Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

Is Selank (Intranasal) appropriate alongside SSRIs or other psychiatric medications?

Selank (Intranasal)'s pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding Selank (Intranasal) to the regimen.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

Is Selank (Intranasal) appropriate alongside SSRIs or other psychiatric medications?

Selank (Intranasal)'s pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding Selank (Intranasal) to the regimen.

Is Selank (Intranasal) appropriate alongside SSRIs or other psychiatric medications?

Selank (Intranasal)'s pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding Selank (Intranasal) to the regimen.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

What is Selank (Intranasal)?

Selank (Intranasal) (also known as Intranasal Selank) is a 7-residue tuftsin-derived heptapeptide (intranasal) with a molecular weight of 751 Da and a plasma half-life of CNS effect hours. Same Selank molecule; olfactory pathway bypasses BBB. The compound is studied primarily in the cognitive / neurological domain for the applications outlined above.

What is the mechanism of action of Selank (Intranasal)?

Same Selank molecule; olfactory pathway bypasses BBB. For cognitive and neurological applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Same Selank molecule; olfactory pathway bypasses BBB. The cognitive / neurological interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What does Selank (Intranasal) stack well with?

For cognitive / neurological protocols, Selank (Intranasal) pairs with compounds on complementary pathways: Semax, Selank, Semax + Selank Blend. These pairings are selected because they engage independent receptor systems from Selank (Intranasal)'s primary mechanism (Same Selank molecule; olfactory pathway bypasses BBB), producing additive or synergistic effects rather than receptor competition.

What is the evidence base for Selank (Intranasal)?

Selank (Intranasal)'s evidence base sits at research level investigational. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The cognitive / neurological interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How does Selank (Intranasal)'s half-life affect dosing?

Selank (Intranasal) has a plasma half-life of CNS effect hours, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under 2-3 sprays daily for 2-4 week courses dosing at 300 mcg per spray per dose explains the typical onset timeline for cognitive and neurological endpoints.

What should I look for in Selank (Intranasal) sourcing and quality?

Acceptable Selank (Intranasal) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 751 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Home/ Compounds/ Selank (Intranasal)

Selank (Intranasal)

Neuroprotection

Researchers tracking Selank (Intranasal) for cognitive and neurological endpoints describe a restorative rather than stimulant phenotype. The compound supports recovery from neurological injury, modulates neuroinflammatory tone, and stabilises monoamine and HPA-axis signalling. Dosing at 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal delivers exposure consistent with the CNS effect hours half-life and the typical 8-12 week cycle pattern used in nootropic-research protocols.

Cognitive / Neurological Applications

Cognitive RecoveryBDNF SupportPost-TBI RecoveryFocus & Executive FunctionMood Stabilisation

Key Takeaways

Cognitive lens: Selank (Intranasal) acts as a restorative compound rather than a stimulant for cognitive endpoints.
CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects.
Mechanism: Same Selank molecule; olfactory pathway bypasses BBB.
Neuro dose: 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal; cognitive effects accumulate across 4-8 weeks.
Cognitive stack partners: Semax, Selank, Semax + Selank Blend.

Cognitive / Neurological Mechanism

Three pathways shape Selank (Intranasal)'s cognitive profile: Same Selank molecule; olfactory pathway bypasses BBB. Each subsection below covers one - CNS access mechanisms, neurotrophic and monoamine effects, and the inflammation-and-recovery layer that often produces the most subjectively reported cognitive shifts.

Cerebral perfusion and the structural cognitive substrate

Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. Selank (Intranasal), with its Same Selank molecule; olfactory pathway bypasses BBB mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The CNS effect hours pharmacokinetic profile supports this restorative rather than stimulant phenotype.

Pharmacokinetics and cognitive dose timing

The CNS effect hours half-life of Selank (Intranasal) via intranasal administration sets the timing window for cognitive effects. At 300 mcg per spray 2-3 sprays daily for 2-4 week courses, receptor occupancy curves and CNS exposure align with the typical multi-week onset profile reported by cognitive-focused users. The standard 2-3 sprays daily for 2-4 week courses dosing pattern is calibrated to maintain therapeutic exposure without continuous saturation, preserving the natural rhythm of the targeted system.

Central nervous system access

Selank (Intranasal) reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's intranasal route(s) and CNS effect hours half-life set the timeline for CNS exposure. Same Selank molecule; olfactory pathway bypasses BBB. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.

Cognitive / Neurological Applications

Cognitive Recovery

For cognitive recovery, Selank (Intranasal) is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.

Mood Stabilisation

Where Selank (Intranasal) is used for mood stabilisation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Long-COVID Cognitive Recovery

Long-COVID Cognitive Recovery is one of the more-reported subjective benefits of Selank (Intranasal) across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.

Serotonin Modulation

For serotonin modulation, Selank (Intranasal) is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300 mcg per spray	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180 mcg per spray	4–6 weeks initial cycle
Neuroprotection focus	Intranasal	300 mcg per spray	2-3 sprays daily for 2-4 week courses
Maintenance phase	Intranasal	210 mcg per spray	Ongoing with periodic pauses

Dose timing for Selank (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Selank (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.

Selank (Intranasal) + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Selank (Intranasal)'s mechanism in cognitive / neurological protocols.
Selank (Intranasal) + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with Selank (Intranasal)'s mechanism in cognitive / neurological protocols.
Selank (Intranasal) + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Selank (Intranasal)'s mechanism in cognitive / neurological protocols.
Selank (Intranasal) + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Selank (Intranasal)'s mechanism in cognitive / neurological protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (Russia approved)

Excellent. Mild nasal irritation possible.

Lens-specific safety considerations for cognitive / neurological use of Selank (Intranasal): Excellent. Mild nasal irritation possible. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Selank in GAD

PMID 21443549

Selank (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Selank (Intranasal)	Tuftsin-derived heptapeptide (intranasal)	CNS effect hours	Neuroprotection
Semax	ACTH-derived nootropic heptapeptide	CNS effect hours; plasma minutes	A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent
Selank	Tuftsin-derived heptapeptide anxiolytic	CNS effect lasts hours; plasma short	A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience
Pinealon	Khavinson tripeptide (pineal-derived)	Short plasma; durable tissue effects	A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models

Frequently Asked Questions

Can Selank (Intranasal) be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

Best route for cognitive applications — injection or intranasal?

For most Selank (Intranasal) cognitive use cases, the route that delivers the compound closest to its target site of action is preferred. Intranasal delivery via the olfactory pathway is the standard for direct CNS access where available.

Does Selank (Intranasal) cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. Selank (Intranasal) produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

How long until I notice cognitive effects?

Mood and gut-related symptoms often shift within 5–14 days. Cognitive recovery and inflammation-related changes accumulate across 4–8 weeks. Stimulant-like 'feel it today' effects are not the typical Selank (Intranasal) profile; the compound is restorative rather than acutely activating.

What is the standard dosing protocol for Selank (Intranasal)?

Conventional Selank (Intranasal) dosing is 300 mcg per spray 2-3 sprays daily for 2-4 week courses via intranasal. For cognitive and neurological use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What class of compound is Selank (Intranasal)?

Selank (Intranasal) is classified as a Tuftsin-derived heptapeptide (intranasal). Within this class, alternative names and analogues include Intranasal Selank. The class-level pharmacology shapes both the clinical applications and the safety profile; the cognitive / neurological literature treats Selank (Intranasal) alongside its class peers when evaluating relative merits.

Clinical Protocol

Start a Selank (Intranasal) Protocol

Alukard provides physician-supervised cognitive protocols with GMP-certified Selank (Intranasal) and GMP-certified compounds and comprehensive neurological assessments.

Get Protocol

Quick Facts

Molecular weight: 751 Da
Sequence length: 7 aa
Half-life: CNS effect hours
WADA: Not on prohibited list
FDA: Unapproved (Russia approved)

Stack Partners

Semax

Selank

Semax + Selank Blend

DSIP

LL-37

Research Note

All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised cognitive protocols

Start Your Cognitive / Neurological Protocol for Selank (Intranasal)

Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised